Back to top
more

Phibro Animal Health (PAHC)

(Delayed Data from NSDQ)

$18.42 USD

18.42
90,943

-0.46 (-2.44%)

Updated Jul 29, 2024 04:00 PM ET

After-Market: $18.41 -0.01 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for PAHC

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Phibro Animal Health Corporation falls in the month of June.

All items in Millions except Per Share data.

6/30/2024 6/30/2023 6/30/2022 6/30/2021 6/30/2020
Assets          
Cash & Equivalents -99,999 81 91 93 91
Receivables NA 163 167 147 127
Notes Receivable NA 0 0 0 0
Inventories NA 278 259 216 197
Other Current Assets NA 63 49 43 37
Total Current Assets NA 586 566 499 452
Net Property & Equipment NA 196 165 155 148
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 108 117 115 124
Deposits & Other Assets NA 82 83 73 60
Total Assets NA 971 932 841 784
Liabilities & Shareholders Equity 6/30/2024 6/30/2023 6/30/2022 6/30/2021 6/30/2020
Notes Payable NA 0 0 0 0
Accounts Payable NA 74 96 68 66
Current Portion Long-Term Debt NA 22 15 9 19
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 80 80 86 72
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 176 191 164 157
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 453 418 383 368
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 60 61 56 70
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 689 669 603 596
Shareholders Equity 6/30/2024 6/30/2023 6/30/2022 6/30/2021 6/30/2020
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 136 136 136 136
Retained Earnings NA 261 248 218 183
Other Equity NA -114 -121 -115 -130
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 283 262 239 188
Total Liabilities & Shareholder's Equity NA 971 932 841 784
Total Common Equity 0 283 262 239 188
Shares Outstanding 40.50 40.50 40.50 40.50 40.40
Book Value Per Share 0.00 6.98 6.48 5.89 4.66

Fiscal Year End for Phibro Animal Health Corporation falls in the month of June.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 99 92 91 81
Receivables NA 161 151 149 163
Notes Receivable NA 0 0 0 0
Inventories NA 282 287 279 278
Other Current Assets NA 55 57 65 63
Total Current Assets NA 597 587 584 586
Net Property & Equipment NA 202 201 193 196
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 103 106 105 108
Deposits & Other Assets NA 77 80 81 82
Total Assets NA 979 973 965 971
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 83 86 77 74
Current Portion Long-Term Debt NA 30 26 24 22
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 77 75 71 80
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 0
Total Current Liabilities NA 189 188 172 176
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 456 449 459 453
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 65 60 60
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 709 702 691 689
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 136 136 136 136
Retained Earnings NA 248 244 248 261
Other Equity NA -114 -110 -111 -114
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 270 271 273 283
Total Liabilities & Shareholder's Equity NA 979 973 965 971
Total Common Equity 0 270 271 273 283
Shares Outstanding 40.50 40.50 40.50 40.50 40.50
Book Value Per Share 0.00 6.67 6.69 6.74 6.98